Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents

Inflammatory Bowel Diseases

Volumn 16, Issue SUPPL. 1, 2010, Pages

  Hanauer, Stephen B ^a   Kornbluth, Asher A ^a   Messick, Julie ^a   Rubin, David T ^a   Sandborn, William J ^a   Sands, Bruce E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 6 METHYLTHIOINOSINE; 6 THIOGUANINE NUCLEOTIDE; ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CORTISONE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLERGY; ARTICLE; BONE DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COLON RESECTION; CROHN DISEASE; CUSHINGOID SYNDROME; DISEASE COURSE; DISEASE MARKER; DRUG FATALITY; DRUG FEVER; EMOTIONAL DISORDER; ENTERITIS; FATIGUE; HEREDITY; HUMAN; INFECTION; MAINTENANCE THERAPY; MALAISE; MENTAL DISEASE; METABOLIC DISORDER; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SEIZURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 78649606965     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21529     Document Type: Article

References (97)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244-250.
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010; 105: 289-297.
3. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994; 107: 3-11.
4. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995; 30: 699-706.
5. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010; 105: 1574-1582.
6. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology. 2006; 130: 650-656.
7. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5: 1430-1438.
8. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008; 135: 1114-1122.
9. Lapidus A, Bernell O, Hellers G, et al. Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology. 1998; 114: 1151-1160.
10. Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology. 1996; 110: 424-431.
11. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002; 97: 947-953.
12. Farmer RG, Easley KA, Rankin GB., Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993; 38: 1137-1146.
13. Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001; 96: 2113-2116. (Pubitemid 32660906)
14. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 15-22.
15. Vermeire S, Van Assche G, Rutgeerts P., Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55: 426-431.
16. Kornbluth A, Sachar DB., Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105: 501-523.
17. Lichtenstein GR, Hanauer SB, Sandborn WJ., Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104: 465-483.
18. Dubinsky MC, Kugathasan S, Mei L, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol. 2008; 6: 1105-1111.
19. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101: 360-367.
20. Henckaerts L, Verstreken I, Van Steen K, et al. Genetic markers and the risk of complicated disease behaviour in Crohn's disease patients. Gastroenterology. 2007; 132: A17.
21. Hanauer SB., Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1570-1582.
22. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121: 255-260.
23. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009; 137: 1934-1943.
24. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 2929-2933.
25. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114: 39-43.
26. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98: 1535-1544.
27. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-1811.
28. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16: 1357-1366.
29. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 1248-1254.
30. Hanauer SB., Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008; 27: 15-21.
31. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 1867-1871.
32. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005; 54: 960-965.
33. Schroeder KW, Tremaine WJ, Ilstrup DM., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625-1629.
34. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991; 115: 350-355.
35. Pentasa (mesalamine) [package insert]. Wayne, PA: Shire US Inc.; June 2008.
36. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 95-102.
37. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132: 66-75.
38. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002; 97: 1398-1407.
39. Truelove SC, Witts LJ., Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955; 1041-1048.
40. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929-936.
41. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5: 103-110.
42. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006; 55: 47-53.
43. Leung Y, Panaccione R, Hemmelgarn B, et al. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008; 53: 1455-1461.
44. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. (Pubitemid 41770166)
45. Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007; 102: 794-802.
46. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009; 137: 1250-1260.
47. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998; 10: 831-835.
48. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-1845.
49. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003; 125: 1025-1031.
50. Svanoni F, Bonassi U, Bagnolo F, et al. Effectiveness of cyclosporine A (CsA) in the treatment of active refractory ulcerative colitis. Presented at: Gastroenterology. 1998; Presentation A1096.
51. Pham CQ, Efros CB, Berardi RR., Cyclosporine for severe ulcerative colitis. Ann Pharmacother. 2006; 40: 96-101.
52. Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006; 4: 760-765.
53. Campbell S, Travis S, Jewell D., Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005; 17: 79-84.
54. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001; 7: 83-88.
55. Armuzzi A, De PB, Lupascu A, et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 2004; 8: 231-233.
56. Ochsenkuhn T, Sackmann M, Goke B., Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol. 2004; 16: 1167-1171.
57. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007; 26: 411-419.
58. Gustavsson A, Järnerot G, Hertervig E., A 2-year follow-up of the Swedish-Danish infliximab/placebo trial in steroid resistant ulcerative colitis. Presented at: Gastroenterology. 2007; Presentation A-146.
59. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol. 2008; 6: 1112-1116.
60. Chaparro M, Burgueno P, Flores EI, et al. Efficacy and safety of infliximab rescue therapy after cyclosporine failure in patients with steroid-refractory ulcerative colitis: a multicenter study. Gastroenterology. 2010; 138: S- 688. Abstract W1274.
61. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979; 77: 847-869.
62. Hanauer SB, Strömberg U., Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004; 2: 379-388.
63. Kane SV, Schoenfeld P, Sandborn WJ, et al. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002; 16: 1509-1517.
64. Sandborn WJ, Feagan BG., Review article: mild to moderate Crohn's disease-defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003; 18: 263-277.
65. Sandborn WJ, Feagan BG, Lichtenstein GR., Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007; 26: 987-1003.
66. Vermeire S, Van Assche G, Rutgeerts P., Review article: Altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther. 2007; 25: 3-12.
67. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37: 674-678.
68. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
69. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250. (Pubitemid 47080388)
70. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
71. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239. (Pubitemid 47300424)
72. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
73. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238.
74. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
75. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006; 130: 1047-1053.
76. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002; 122: 904-915.
77. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 1133-1139.
78. Cosnes J, de Parades V, Carbonnel F, et al. Classification of the sequelae of bowel resection for Crohn's disease. Br J Surg. 1994; 81: 1627-1631.
79. Mamula P, Markowitz JE, Baldassano RN., Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am. 2003; 32: 967-995, viii.
80. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412-422.
81. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99: 956-963.
82. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997; 112: 1475-1481.
83. D'Haens G, Geboes K, Rutgeerts P., Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999; 50: 667-671.
84. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110: 353-356.
85. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990; 98: 811-818.
86. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442.
87. D'Haens G, Baert F, Van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667.
88. Rutgeerts P, D'Haens G, Van Assche G., Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease-first results of the Extend Trial. Presented at: Gastroenterology. 2009; Presentation A-116.
89. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010; 138: 463-468.
90. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1295-1301.
91. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441-450.
92. Lichtenstein GR, Rubin D, Regalli G, et al. Endoscopically measured mucosal healing of delayed-release oral mesalamin 4.8 g/day versus 2.4 g/day (Abstract T1127). Gastroenterology. 2006; 130: A479-A480.
93. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results of a prospective, multicenter study. Gastroenterology. 2006; 130: A-197.
94. Rutter M, Saunders M, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459.
95. Rubin D, Huo D, Rothe JA, et al. Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective review of pathology (Abstract 14). Gastroenterology. 2006; 130: A2.
96. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105.
97. Higgins PD, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol. 2005; 100: 355-361.